HUTCHMED (China) Ltd
HCM17.040USD
-0.410-2.35%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
14.86BMarktkapitalisierung
--KGV TTM
mehr Informationen über HUTCHMED (China) Ltd Unternehmen
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Unternehmensinformationen
BörsenkürzelHCM
Name des UnternehmensHUTCHMED (China) Ltd
IPO-datumMay 19, 2006
CEODr. Weiguo Su, Ph.D.
Anzahl der mitarbeiter1811
WertpapierartOrdinary Share
GeschäftsjahresendeMay 19
Addresse48th Floor, Cheung Kong Center, 2 Queen's Road Central
Stadt
BörseHochiminh Stock Exchange
LandHong Kong
Postleitzahl- -
Telefon85221281188
Websitehttps://www.hutch-med.com/
BörsenkürzelHCM
IPO-datumMay 19, 2006
CEODr. Weiguo Su, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Mon, Aug 18
Aktualisiert: Mon, Aug 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Schroder Investment Management (Singapore) Ltd.
1.02%
Allianz Global Investors Asia Pacific Limited
0.50%
Schroder Investment Management (Hong Kong) Ltd.
0.46%
State Street Global Advisors (US)
0.19%
AIA Group Ltd
0.18%
Andere
97.65%
Aktionäre
Aktionäre
Anteil
Schroder Investment Management (Singapore) Ltd.
1.02%
Allianz Global Investors Asia Pacific Limited
0.50%
Schroder Investment Management (Hong Kong) Ltd.
0.46%
State Street Global Advisors (US)
0.19%
AIA Group Ltd
0.18%
Andere
97.65%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
2.38%
Investment Advisor
0.70%
Research Firm
0.30%
Hedge Fund
0.24%
Individual Investor
0.12%
Sovereign Wealth Fund
0.01%
Andere
96.25%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
160
6.97M
3.99%
-6.31M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
2023Q2
352
26.00M
15.01%
-20.74M
2023Q1
364
26.52M
15.33%
-22.52M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Schroder Investment Management (Singapore) Ltd.
1.87M
1.07%
+570.74K
+43.88%
Mar 31, 2025
Allianz Global Investors Asia Pacific Limited
945.74K
0.54%
-117.52K
-11.05%
Mar 31, 2025
Schroder Investment Management (Hong Kong) Ltd.
972.00K
0.56%
-496.17K
-33.80%
Mar 31, 2025
State Street Global Advisors (US)
336.87K
0.19%
-10.74K
-3.09%
Mar 31, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
93.92K
0.05%
+7.34K
+8.48%
Mar 31, 2025
M&G Investment Management Ltd.
258.69K
0.15%
-7.09K
-2.67%
Mar 31, 2025
Su (Weiguo Ph.D.)
183.98K
0.11%
+183.98K
--
Mar 04, 2024
Jane Street Capital, L.L.C.
222.24K
0.13%
+124.77K
+128.01%
Mar 31, 2025
Amundi Asset Management, SAS
157.43K
0.09%
-12.82K
-7.53%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
